Mechanism of FODMAP Restriction on FGID Patients
Launched by UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTRE · May 28, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different types of diets, specifically those that limit certain carbohydrates known as FODMAPs, can affect patients with Functional Gastrointestinal Disorders (FGIDs) like Irritable Bowel Syndrome (IBS) and Functional Dyspepsia. The researchers want to understand how these diets impact gut health, symptoms, and overall well-being. Participants will be assigned to one of three diets: a low FODMAP diet, a Gentle FODMAP diet, or Traditional Dietary Advice based on current guidelines. They will follow their assigned diet for two weeks and will provide stool and blood samples, along with keeping a food diary and filling out questionnaires about their health.
To be eligible for this trial, participants need to be at least 18 years old and able to give consent. They should have IBS or Functional Dyspepsia as diagnosed by a doctor and be able to communicate in Malay or English. Certain individuals, such as those who are pregnant, have specific gastrointestinal diseases, or are currently taking certain medications, will not be able to participate. This trial is currently in the planning stage and has not yet started recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 and above
- • Able to provide informed consent
- • Those with pre-existing irritable bowel syndrome (IBS) or functional dyspepsia (FD) or both screened by gastroenterologists
- • Meet the ROME III- Asian criteria for FGID
- • Able to communicate in Malay or English language
- Exclusion Criteria:
- • Pregnant or lactating women
- • History declared by the participant of pre-existing gastrointestinal disorder, including but not limited to Inflammatory Bowel Disease, Coeliac Disease, Pancreatitis, Gallstone disease (biliary colic, cholecystitis), Diverticulitis
- • Cancer of any kind
- • Patients with reported history of previous resection of any part of the GI tract other than appendix or gall bladder, intestinal stoma
- • Habitual use of opiate analgesics likely to alter bowel function e.g. morphine
- • Use of antibiotics in the preceding two weeks and/or in the past one month
- • Consumption of probiotics, prebiotics or fibre supplements in the past one month
- • Enteral feeding or texture modified diet patients
- • Those with cognitive impairment or severe mental disorder (Alzheimer's, schizophrenia, bipolar disorder. etc)
- • Shift workers (e.g. Nurse, doctors)
About Universiti Kebangsaan Malaysia Medical Centre
Universiti Kebangsaan Malaysia Medical Centre (UKMMC) is a premier academic medical institution dedicated to advancing healthcare through innovative research, education, and patient care. As a leading sponsor of clinical trials, UKMMC engages in cutting-edge studies that aim to enhance medical knowledge and improve treatment outcomes across various disciplines. With a commitment to ethical practices and rigorous scientific methodologies, UKMMC collaborates with multidisciplinary teams to ensure the highest standards of research integrity and participant safety, ultimately contributing to the global medical community and the health of the population.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuala Lumpur, , Malaysia
Patients applied
Trial Officials
Neoh Hui-Min, Assc. Prf
Study Chair
National University of Malaysia
Vanitha Mariappan, Dr
Study Chair
National University of Malaysia
Deborah Chia Hsin Chew, Dr
Study Chair
National University of Malaysia
Syaratul Dalina Yusoff, Dr
Study Chair
National University of Malaysia
Yee Xing You, Dr
Study Chair
National University of Malaysia
Yeong Yeh Lee, Prof
Study Chair
Universiti Sains Malaysia
Jaysrina Mahalinga Moorthy, Ms
Study Director
National University of Malaysia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported